A 2010 inspection revealed that the company had marketed its NuBone Osteoinductive Bone Graft product without prior approval or clearance. The settlement requires the Pennsylvania-based medical device firm to pay a $550,000 penalty and the firm’s CEO, David Paul, to pay a $450,000 penalty, for a total of $1 million.
Related Articles on Supply Chain:
FDA Seeks Stricter Regulations on Hip Implants, Vaginal Mesh
Medical Device Industry Reps to Discuss Medical Device Tax With Lawmakers
New Michigan Podiatric Group Looks to Contract Directly With Insurers, Vendors
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.